Hydroxyurea Medac

Hydroxycarbamide, the active ingredient in Hydroxyurea Medac, is an antimetabolite presented as a tablet for oral use. It treats sickle cell disease and several hematologic malignancies in adult patients.

GNH USA supplies Hydroxyurea Medac as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Hydroxyurea is employed in hematologic and oncologic disorders to modify disease pathways and improve clinical outcomes.

- Sickle cell disease: increases fetal hemoglobin production, reducing vaso‑occlusive crises. - Chronic myelogenous leukemia: suppresses leukemic cell proliferation. - Polycythemia vera: lowers red blood cell mass and reduces thrombosis risk. - Essential thrombocythemia: decreases platelet count and mitigates thrombotic events. - Melanoma: used as part of combination therapy to inhibit tumor growth.

Hydroxyurea may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Bone marrow suppression: decreased blood cell counts. - Gastrointestinal upset: nausea, vomiting, abdominal pain. - Skin changes: rash or hyperpigmentation. - Hair loss: alopecia. - Mouth ulcers: oral mucositis.

Serious or Rare Side Effects: - Severe cytopenias: life‑threatening neutropenia or thrombocytopenia. - Renal toxicity: acute kidney injury. - Hepatic dysfunction: elevated transaminases. - Hypersensitivity reactions: anaphylaxis or severe rash. - Secondary malignancies: rare leukemic transformation.

When prescribing hydroxyurea, clinicians should consider several safety precautions to minimize risks. - Baseline blood counts: obtain a complete blood count before initiation and monitor regularly. - Renal function: assess serum creatinine and adjust dosing if impairment is present. - Hepatic function: monitor liver enzymes during therapy. - Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks. - Concomitant myelosuppressive agents: avoid or use with heightened caution. - Store below 25°C: keep in the original packaging, protect from moisture.

Hydroxyurea can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive drugs (e.g., azathioprine, cyclophosphamide): risk of profound bone marrow suppression. - Live vaccines: increased risk of infection. - Antiretroviral protease inhibitors (e.g., ritonavir): may increase hydroxyurea plasma levels. - Allopurinol: may enhance hydroxyurea toxicity. - High‑dose vitamin C: may increase oxidative stress.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal function when combined. - Antacids containing aluminum or magnesium: may reduce hydroxyurea absorption. - Phenytoin: may alter hydroxyurea metabolism. - Methotrexate: additive myelosuppression risk. - Sulfonylureas: potential for enhanced hypoglycaemia.